ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAIVE AND RELAPSED/REFRACTORY PATIENTS

被引：0
|
作者：
Navada, S. [1 ]
Garcia-Manero, G. [2 ]
Hearn, K. [2 ]
Odchimar-Reissig, R. [1 ]
Demakos, E. [1 ]
Fenaux, P. [3 ]
Petrone, M. [4 ]
Zbyszewski, P. [4 ]
Fruchtman, S. [4 ]
Silverman, L. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Hop St Louis Univ, Paris, France
[4] Onconova Therapeut, Newtown, PA USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S488
引用
收藏
页码：183 / 184
页数：2
相关论文
共 50 条
  • [1] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [2] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [3] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    [J]. BLOOD, 2014, 124 (21)
  • [4] Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Navada, Shyamala C.
    Baer, Maria R.
    Raza, Azra
    Greenberg, Peter
    Kreuzer, Karl-Anton
    Hiwase, Devendra K.
    Roboz, Gail J.
    Santini, Valeria
    Platzbecker, Uwe
    Petrone, Michael E.
    Brownstein, Bernard
    Zbyszewski, Patrick Simon
    Maniar, Manoj
    Silverman, Lewis R.
    [J]. BLOOD, 2016, 128 (22)
  • [5] COMBINATION OF ORAL RIGOSERTIB AND INJECTABLE AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S30 - S30
  • [6] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    [J]. BLOOD, 2012, 120 (21)
  • [7] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2015, 126 (23)
  • [8] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Laille, E.
    Ward, R.
    Nasser, A.
    Stoltz, M.
    Cogle, C.
    Gore, S.
    Skikne, B. S.
    Garcia-Manero, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase 2 Expansion Study of Oral Rigosertib Combined With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment-Naive and Relapsed/Refractory Patients
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 9
  • [10] A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
    Navada, Shyamala C.
    Fruchtman, Steven M.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Petrone, Michael E.
    Zbyszewski, Patrick S.
    Holland, James F.
    Silverman, Lewis R.
    [J]. LEUKEMIA RESEARCH, 2018, 64 : 10 - 16
12345